Semaglutide
STEP 1
Novo Nordisk · Phase 3 · Completed · Enrollment 1961
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide s.c. 2.4 mg once weekly | Obesity or overweight | 2.4 mg | 68 | ITT | -14.9% at week 68 |
| Semaglutide placebo | Obesity or overweight | n/r | 68 | ITT | -2.4% at week 68 |